A Phase III, Randomized, Controlled, Multi-centre, 3-Arm Study of NeoadjuvantOsimertinib as Monotherapy or in Combination with Chemotherapy versus Standard ofCare Chemotherapy Alone for the Treatment of Patients with Epidermal Growth FactorReceptor Mutation Positive, Resectable Non-small Cell Lung Cancer (NeoADAURA)
Study of Osimertinib (TAGRISSOTM) in Non-Small Cell Lung Cancer (NeoADAURA) Patients
Sponsor: AstraZeneca
Enrolling: Male and Female Patients
IRB Number: AAAT5068
U.S. Govt. ID: NCT04351555
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to see whether the medication osimertinib (TAGRISSOTM) alone or when used in combination with chemotherapy is more effective than chemotherapy alone for the treatment of early stage Non-Small Cell Lung Cancer prior to surgery. Osimertinib is an EGFR TKI therapy that targets EGFR mutations. When a tumor is found to have this type of mutation, there is a class of drugs known as EGFR tyrosine kinase inhibitors (TKIs) which target the mutation to treat the patient.
Catherine Shu, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Do you have Non-Small Cell Lung Cancer, that is able to be removed? Yes No
Do you have a life expectancy of greater than 6 months? Yes No
Do you have a history of organ transplantation? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator